scholarly journals Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model

2016 ◽  
Vol 22 (4) ◽  
pp. 378-384 ◽  
Author(s):  
Max Seidensticker ◽  
Sebastian Streit ◽  
Norbert Nass ◽  
Christian Wybranski ◽  
Julian Jürgens ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Tumor ◽  
Transarterial Chemoembolization ◽  
Tumor Model ◽  
Rabbit Liver ◽  
Efficacy And Safety

scholarly journals Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model

Theranostics ◽  
2019 ◽  
Vol 9 (13) ◽  
pp. 3674-3686 ◽  
Author(s):  
Johanna Maria Mijntje van Breugel ◽  
Jean-François Geschwind ◽  
Sahar Mirpour ◽  
Lynn Jeanette Savic ◽  
Xuchen Zhang ◽  
...  
Keyword(s):  
Liver Tumor ◽  
Transarterial Chemoembolization ◽  
Tumor Model ◽  
Rabbit Liver

Correlation between Hepatic Tumor Blood Flow and Glucose Utilization in a Rabbit Liver Tumor Model

Radiology ◽  
2006 ◽  
Vol 239 (3) ◽  
pp. 740-750 ◽  
Author(s):  
Errol E. Stewart ◽  
Xaiogang Chen ◽  
Jennifer Hadway ◽  
Ting-Yim Lee
Keyword(s):  
Blood Flow ◽  
Liver Tumor ◽  
Glucose Utilization ◽  
Tumor Model ◽  
Hepatic Tumor ◽  
Rabbit Liver ◽  
Tumor Blood Flow

Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect

2016 ◽  
Vol 27 (7) ◽  
pp. 1086-1092 ◽  
Author(s):  
Gyoung Min Kim ◽  
Man Deuk Kim ◽  
Do Young Kim ◽  
Se Hoon Kim ◽  
Jong Yun Won ◽  
...  
Keyword(s):  
Liver Tumor ◽  
Transarterial Chemoembolization ◽  
Antitumor Effect ◽  
Tumor Model

scholarly journals Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) Study

2020 ◽  
Vol 28 (1) ◽  
pp. 75-94 ◽  
Author(s):  
Junhui Sun ◽  
Guanhui Zhou ◽  
Xiaoxi Xie ◽  
Wenjiang Gu ◽  
Jing Huang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Portal Vein ◽  
Treatment Response ◽  
Transarterial Chemoembolization ◽  
Efficacy And Safety ◽  
Portal Vein Invasion ◽  
Drug Eluting Beads ◽  
Drug Eluting ◽  
The Mean

The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response rate (ORR) were 22.9%, 60.7%, and 83.6%, respectively. The mean PFS was 362 (95% CI: 34.9‐375) days, the 6-month PFS rate was 89.4 ± 2.1%, while the mean OS was 380 (95% CI: 370‐389) days, and the 6-month OS rate was 94.4 ± 1.7%. Multivariate logistic regression revealed that portal vein invasion (p = 0.011) was an independent predictor of worse clinical response. Portal vein invasion (p = 0.040), previous cTACE treatment (p = 0.030), as well as abnormal serum creatinine level (BCr) (p = 0.017) were independent factors that predicted worse ORR. In terms of survival, higher Barcelona Clinic Liver Cancer (BCLC) stage (p = 0.029) predicted for worse PFS, and abnormal albumin (ALB) (p = 0.011) and total serum bilirubin (TBIL) (p = 0.009) predicted for worse OS. The number of patients with abnormal albumin, total protein (TP), TBIL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were augmented at 1 week posttreatment and were similar at 1‐3 months compared with baseline. The most common AEs were pain, fever, nausea, and vomiting, and no severe AEs were observed in this study. DEB-TACE was effective and tolerable in treating Chinese HCC patients, and portal vein invasion, previous cTACE treatment, abnormal BCr, ALB, and TBIL appear to be important factors that predict worse clinical outcome.

Intraarterial Therapy Using Micellar Nanoparticles Incorporating SN-38 in a Rabbit Liver Tumor Model

2017 ◽  
Vol 28 (3) ◽  
pp. 457-464 ◽  
Author(s):  
Hideyuki Nishiofuku ◽  
Toshihiro Tanaka ◽  
Yasushi Fukuoka ◽  
Takeshi Sato ◽  
Tetsuya Masada ◽  
...  
Keyword(s):  
Liver Tumor ◽  
Tumor Model ◽  
Rabbit Liver ◽  
Intraarterial Therapy ◽  
Micellar Nanoparticles

scholarly journals Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study

2020 ◽  
Vol 19 ◽  
pp. 153303382096558
Author(s):  
Wenbo Guo ◽  
Song Chen ◽  
Zhiqiang Wu ◽  
Wenquan Zhuang ◽  
Jianyong Yang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Rate ◽  
Transarterial Chemoembolization ◽  
Statistical Tests ◽  
Objective Response ◽  
Rank Test ◽  
P Value ◽  
Efficacy And Safety ◽  
Unresectable Hepatocellular Carcinoma ◽  
Survival Difference

Objective: This study aimed to explore the efficacy and safety of using transarterial chemoembolization (TACE) combined with anlotinib in patients with unresectable hepatocellular carcinoma, compared with TACE alone. Methods: This was a single-center study, retrospectively recruited 82 unresectable HCC patients who received either TACE alone (TA group; n = 46) or TACE combined with anlotinib (TC group; n = 36) between Jan 2018 and Jan 2019. The primary outcomes were progression-free survival (PFS) and overall survival (OS). While the secondary outcomes were the objective response rate (ORR), the disease control rate (DCR), and main complications. Log-rank test and Kaplan–Meier method was used to calculate the survival difference. All statistical tests were 2-sided and P value <0.05 were taken as statistically significant. Results: Patients in TC group had a significant higher PFS than those in TA group (7.35 months vs. 5.54 months, p = 0.035). Although 3-month survival rate in the 2 groups was not statistically different (97.2% vs. 93.5%, p = 0.627), the survival rate at 6 months and 1 year were strongly higher in TC group (83.3% vs. 56.5%, p = 0.016; 66.7% vs. 19.6%, respectively, p < 0.05). Furthermore, there was a significantly higher ORR in TC group, while no statistical difference existed in DCR. Neither treatment-related mortality nor grade 4 adverse events (AEs) occurred. However, 2 patients in TC group had grade 3 AEs (one suffered with erythra, and the other with hand-foot-skin reaction), which disappeared after prompt treatment. Conclusion: TACE combined with anlotinib is safe and may improve outcomes for unresectable HCC patients comparing with TACE alone. Randomized controlled trials are warranted to further evaluate treatment effects of anlotinib in HCC.

Sign in / Sign up

Export Citation Format

Share Document